Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now ...

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...

A new study developed a mineralized DNA hydrogel that combines immune regulation with sustained bone regeneration. Using ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

In a recent study posted to the bioRxiv* preprint server, researchers performed age-reversing experiments, in vivo and in vitro, in progeroid mice using gene therapy. Study: Gene Therapy Mediated ...

The result is a widely anticipated landmark for rejuvenation technology. A small biotech company claims it has used a technology called reprogramming to rejuvenate old mice and extend their lives, a ...

Researchers have attained the holy grail of cellular reprogramming: inducing pluripotency without using any DNA-based materials. Using only a cocktail of purified proteins and a chemical additive, ...

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...